NASDAQ 100 % ()
FTSE 100 % ()
S&P 500 % ()
BTC/USD % ()
XRP/USD % ()
ETH/USD % ()
GBP/USD % ()
GOLD % ()
SILVER % ()

IDYA

IDYA US Stock
$19
Open: $20.53 High: $20.53 Low: $17.75 Close: $18.6
Range: 2021-04-19 - 2021-04-20
Volume: 402,476
Market: Extended-hours
Powered by Finage Stock APIDelayed data
IDYA
  • CEO:
  • Employees:
  • Sector:
  • Industry:
IDYA News
Latest news about the IDYA
  • IDEAYA Biosciences Announces Agenda for Inaugural Synthetic Lethality Investor Day on Tuesday, April 20, 2021

    IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the agenda for its inaugural Synthetic Lethality Investor Day. The event will be held virtually on Tuesday, April 20, 2021, at 1:00 pm - 3:00 pm ET (10:00 am - 12:00 noon PT). The agenda will include scientific presentations from IDEAYA, GlaxoSmithKline (GSK) and several key opinion leaders.

    View More →
  • 2 Biotech Start-Ups Are Searching for Cancer’s Hidden Weaknesses. What to Know.

    Biotech startups Repare Therapeutics and Ideaya Biosciences, along with Big Pharma partners, are now leading clinical trials for new drugs.

    View More →
  • IDEAYA Reports Darovasertib (IDE196) Monotherapy Overall Survival Data and Observes Early Partial Responses in Binimetinib Combination in Metastatic Uveal Melanoma

    IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced clinical data from the ongoing Phase 1/2 trial evaluating darovasertib (IDE196) monotherapy and binimetinib combination therapy in patients with solid tumors, including Metastatic Uveal Melanoma (MUM) and Skin Melanoma (ClinicalTrials.gov Identifier: NCT03947385).

    View More →
  • IDEAYA Announces Investor Day Webcast to Review Clinical Data from Phase 1/2 Trial of Darovasertib (IDE196) Monotherapy and Combination with Binimetinib in Metastatic Uveal Melanoma

    IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that the company plans to issue a pre-market press release and conduct a webcast on Friday, April 16, 2021, to discuss clinical data from the ongoing Phase 1/2 trial evaluating darovasertib (IDE196) as monotherapy and darovasertib and binimetinib combination in patients with metastatic uveal melanoma (MUM) (ClinicalTrials.gov Identifier: NCT03947385).

    View More →
  • IDEAYA Announces Dosing of First Patient of MAT2A Inhibitor IDE397 in Phase 1 Clinical Trial Evaluating MTAP-Deletion Solid Tumors

    IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced First-Patient-In (FPI) in the Phase 1 clinical trial evaluating IDE397 (ClinicalTrials.gov Identifier: NCT04794699). IDE397 is a potential best-in-class methionine adenosyltransferase 2a (MAT2A) inhibitor being evaluated in cancer patients harboring methylthioadenosine phosphorylase (MTAP) deletion.

    View More →
  • IDEAYA Posts Better-Than-Feared Quarterly Loss, Sales Top Estimates

    IDEAYA Biosciences, a synthetic lethality-focused precision medicine oncology company, reported a smaller-than-expected loss in the fourth quarter and outpaced analysts’ expectations for revenues. IDEAYA (IDYA) incurred a loss of $0.18 per share in 4Q, compared to the loss of $0.53 recorded in the prior-year quarter. Analysts were expecting the company to report a loss of $0.30 per share. Total collaboration revenue of $10.6 million topped analysts’ expectations of $7.92 million. Research and development expenses were $12.1 million, up 42.4% year-over-year, while general and administrative expenses came in at $3.8 million, up 35.7%. (See IDEAYA stock analysis on TipRanks) IDEAYA CEO Yujiro S. Hata said, “IDE196 has reached a key inflection point as we initiated dose expansion in our Phase 1/2 study evaluating the IDE196 / binimetinib combination in the GNAQ/11 mutation-driven cancer of metastatic uveal melanoma.” On March 17, Oppenheimer analyst Kevin DeGeeter maintained a Buy rating and a price target of $25 (7.5% upside potential) on the stock. DeGeeter views “partnership with GSK as validation of IDYA’s leading role in synthetic lethality drug development. Additionally, PKC inhibition, which is regulated by MAPK signaling of upstream GNA11 or GNAQ mutations, offers an attractive strategy for treating metastatic uveal melanoma based on broad expression of GNA11 or GNAQ mutations in the population (90%-plus of patients) and early-stage proof-of-concept from clinical trials.” IDEAYA shares have exploded 96.4% over the past six months, while the stock still scores a Strong Buy consensus rating based on 6 unanimous Buys. That’s alongside an average analyst price target of $26.80, which implies 15.3% upside potential to current levels. Related News: FedEx Posts Better-Than-Expected 3Q Results As Sales Outperform; Shares Gain 4.4% Ollie’s 4Q Results Beat Analysts’ Expectations As Sales Pick Up; Shares Gain After-Hours Embraer Posts Smaller-Than-Feared Quarterly Loss; Shares Pop 7% More recent articles from Smarter Analyst: Mondelez Agrees To Buy Grenade; Street Sees 12% Upside Eaton Snaps Up Green Motion SA In EV Push Banc Of California Snaps Up Pacific Mercantile Bancorp For $9.77 Per Share SeaSpine To Snap Up 7D Surgical; Street Remains Bullish

    View More →
  • IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss, Lags Revenue Estimates

    IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 0.00% and -2.84%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

    View More →
  • IDEAYA Biosciences, Inc. Reports Fourth Quarter 2020 Financial Results and Provides Business Update

    IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update and announced financial results for the fourth quarter ended December 31, 2020.

    View More →
  • IDEAYA Announces Dose Expansion in Phase 1/2 Study of IDE196 and Binimetinib Combination in Metastatic Uveal Melanoma Based on Early Clinical Activity

    IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced dose expansion of the ongoing Phase 1/2 study (ClinicalTrials.gov Identifier: NCT03947385) evaluating the combination of IDE196 and binimetinib in metastatic uveal melanoma (MUM). IDEAYA is the sponsor of this combination study, which is being conducted pursuant to a clinical trial collaboration and drug supply agreement with Pfizer. IDE196 is IDEAYA's clinical stage protein kinase C, or PKC, inhibitor and binimetinib is a MEK inhibitor to which Pfizer has exclusive rights in the U.S. and Canada.

    View More →
  • IDEAYA Announces Presentations at AACR Annual Meeting 2021 for Synthetic Lethality Programs IDE397 and PARG, and Kinase Inhibitor IDE196

    IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced publication of abstracts at the 2021 Annual Meeting of the American Association for Cancer Research (AACR). IDEAYA will present data for its potential first-in-class synthetic lethality programs IDE397, a Phase 1 methionine adenosyltransferase 2a (MAT2A) inhibitor, poly (ADP-ribose) glycohydrolase (PARG) for which a development candidate is targeted in 2021, and IDE196, a Phase 1/2 protein kinase C (PKC) inhibitor targeting GNAQ/11-mutation cancers.

    View More →
  • IDEAYA to Participate in Upcoming March 2021 Investor Relations Events

    IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the following upcoming investor relations events.

    View More →
  • IDEAYA Biosciences Announces Inaugural Synthetic Lethality Investor Day

    IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced IDEAYA's inaugural Synthetic Lethality Investor Day, with scientific presentations from IDEAYA, GlaxoSmithKline (GSK) and several Key Opinion Leaders, will be held virtually on Tuesday, April 20, 2021, at 1:00 pm - 3:00 pm ET / 10:00 am - 12:00 pm PT.

    View More →
  • IDEAYA Biosciences Appoints Susan L. Kelley, M.D., an Industry Veteran in Medical Oncology and Clinical Development, to its Board of Directors

    IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the appointment of Susan Kelley, M.D., to its Board of Directors.

    View More →
  • Announcing: IDEAYA Biosciences (NASDAQ:IDYA) Stock Increased An Energizing 178% In The Last Year

    Unless you borrow money to invest, the potential losses are limited. But if you pick the right stock, you can make a...

    View More →
  • IDEAYA Announces IDE397 IND Clearance by U.S. FDA to Initiate Phase 1 and Appointment of Matthew Maurer, M.D., as Vice President, Head of Clinical Oncology and Medical Affairs

    IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the effectiveness of the Investigational New Drug (IND) application for a Phase 1 clinical trial to evaluate IDE397, a potential best-in-class methionine adenosyltransferase 2a (MAT2A) inhibitor.

    View More →
  • IDEAYA to Participate in Upcoming February 2021 Investor Relations Events

    IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced its participation at the following upcoming investor relations events.

    View More →
  • Spelman College and IDEAYA Biosciences Announce Partnership for Professional Development of the Next Generation of Female African American Leaders in the Biotechnology Industry

    Spelman College and IDEAYA Biosciences, Inc. (Nasdaq: IDYA) announce partnership for professional development of the next generation of female African American leaders in the biotechnology industry through the Spelman College and IDEAYA Biosciences Health Science and Biotechnology Program.

    View More →
  • IDEAYA Biosciences Announces Submission of IND Application for MAT2A Development Candidate IDE397 with the U.S. FDA

    IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, today announced it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial to evaluate IDE397, a small molecule methionine adenosyltransferase 2a (MAT2A) inhibitor, for the treatment of patients having solid tumors with methylthioadenosine phosphorylase (MTAP) deletion.

    View More →
  • IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Crizotinib, a cMET Inhibitor

    IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, announced First-Patient-In (FPI) in the Phase 1 combination study of IDE196 and crizotinib, a cMET inhibitor, in metastatic uveal melanoma (MUM). The clinical combination of IDE196 and crizotinib is being evaluated by IDEAYA in collaboration with Pfizer pursuant to a clinical trial collaboration and supply agreement.

    View More →
  • IDEAYA to Participate in Upcoming January 2021 Investor Relations Events and Scientific Conferences

    IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced its participation at the following upcoming investor relations events and scientific conferences.

    View More →